Australian Chlamydia Control Effectiveness Pilot - ACCEPt

Lead Researcher Email Number Webpage

Project Details

This world first trial aims to determine the effectiveness, cost-effectiveness, acceptability and feasibility of a chlamydia testing intervention in general practice. It will determine whether annual chlamydia testing for 16 to 29 year old men and women will reduce the prevalence of chlamydia in the population and will make recommendations to the government about whether it should introduce a national chlamydia testing program. The trial protocol has been published online as a Lancet Accepted Protocol (Hocking JS, Low N, Guy R, Law M, Donovan B, Kaldor J, Temple-Smith M, Gunn J, Fairley CK. 12 PRT 09010: Australian Chlamydia Control Effectiveness Pilot (ACCEPt): a cluster randomised controlled trial of chlamydia testing in general practice (ACTRN1260000297022) Lancet protocol. Published online, May 2013.)

Project summary

Chlamydia trachomatis is the most commonly reported sexually transmitted infection in Australia. As over 80% of infections are asymptomatic, screening is the main way to detect cases. However, there is considerable uncertainty about the evidence supporting population-based chlamydia screening and this has led to much debate. In response, the Australian Government funded the Australian Chlamydia Control Effectiveness Pilot (ACCEPt), a cluster randomised controlled trial of a chlamydia screening intervention in general practice. ACCEPt was commenced in July 2010 and is a world first trial of annual chlamydia screening in general practice. A total of 150 GP clinics in 54 rural towns in 4 Australian states are enrolled – over 90% of clinics approached agreed to participate. A chlamydia screening intervention comprising incentive payments per test, computer alerts reminding GPs to screen and quarterly reports on each GP's chlamydia screening rates has been implemented. Prior to randomization chlamydia prevalence was estimated among 4,300 men and women aged 16 to 29 years attending participating clinics – a prevalence of 4.6% was found. This prevalence will be re-estimated at the conclusion of the trial.  The intervention period is ongoing and to date, testing rates have more than doubled in intervention clinics compared with control.


Professor Jane Hocking

Anna Wood

Alaina Vaisey

Eris Smyth

Michelle King

Anna Yeung

Belinda Ford (University of New South Wales)

Rebecca Lorch (University of New South Wales)


Department of Health and Ageing, NHMRC, Department of Health, Victoria, NSW Health. Further in-kind support has been provided from the Royal Australian College of General Practitioners and the Australian Primary Health Care Nurse Association.

Research Group

Sexual Health

Faculty Research Themes

Infection and Immunology

School Research Themes

Screening and early detection of disease

Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Centre for Epidemiology and Biostatistics

Unit / Centre

Sexual Health